STOCK TITAN

Elevation Oncology Inc - ELEV STOCK NEWS

Welcome to our dedicated news page for Elevation Oncology (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elevation Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elevation Oncology's position in the market.

Rhea-AI Summary
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary
Elevation Oncology, Inc. (ELEV) announces financial results for Q4 2023, raises $17.0M, and advances clinical trials globally. The company plans to provide updates on Phase 1 trials, present preclinical data, and nominate development candidates in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Elevation Oncology presents preclinical proof-of-concept data for its HER3-targeting antibody-drug conjugate program at AACR 2024, aiming to nominate a development candidate in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Elevation Oncology, Inc. appoints Julie Cherrington, Ph.D., and Alan Sandler, M.D., to its Board of Directors, aiming to advance selective cancer therapies. Dr. Cherrington brings extensive drug development experience, while Dr. Sandler contributes expertise in oncology and drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
management clinical trial
-
Rhea-AI Summary
Elevation Oncology, Inc. (Nasdaq: ELEV) announces participation in upcoming investor conferences in March 2024 to discuss innovative cancer therapies for solid tumors with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
conferences
-
Rhea-AI Summary
Elevation Oncology expands Phase 1 clinical trial of EO-3021 outside the US, dosing first patient in Japan. The trial aims to evaluate safety, tolerability, and anti-tumor activity in patients with advanced solid tumors expressing Claudin 18.2. Positive responses from medical experts highlight the potential of EO-3021 to address unmet medical needs in gastric cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
Rhea-AI Summary
Elevation Oncology, Inc. (Nasdaq: ELEV) has appointed Darcy Mootz, Ph.D., an experienced life sciences executive, to its Board of Directors. Dr. Mootz brings expertise in corporate strategy, corporate development, finance, and operations. She is expected to provide important perspective as the company continues to advance EO-3021 through clinical development. Dr. Mootz's appointment is seen as a significant step in the company's efforts to build a pipeline of selective cancer therapies for a range of unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.46%
Tags
management
-
Rhea-AI Summary
Elevation Oncology, Inc. (Nasdaq: ELEV) announces updates on ongoing Phase 1 clinical trial of EO-3021, expansion of clinical development program, and strong financial position for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.8%
Tags
none
-
Rhea-AI Summary
Elevation Oncology, Inc. (ELEV) CEO to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
conferences
Rhea-AI Summary
Elevation Oncology has announced financial results for Q3 2023, with cash totaling $94.8 million. They have initiated patient enrollment in the Phase 1 clinical trial for EO-3021, a potential anti-Claudin 18.2 ADC therapy. Preliminary safety and anti-tumor activity data are expected in 1H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Elevation Oncology Inc

Nasdaq:ELEV

ELEV Rankings

ELEV Stock Data

230.12M
19.16M
1.97%
86.3%
10.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About ELEV

elevation oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. we make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. our lead candidate, seribantumab, inhibits tumor growth driven by nrg1 fusions and is currently being clinically tested in the phase 2 crestone study for patients with tumors of any origin that have an nrg1 fusion. learn more about crestone at www.nrg1fusion.com. elevation oncology is backed by aisling capital, vertex ventures hc, qiming venture partners usa, driehaus capital management, and bvf partners.